Skip to search formSkip to main contentSkip to account menu

OPT 80

Known as: OPT-80, OPT80 cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Fidaxomicin (formerly OPT-80) is a narrow-spectrum investigational, nonabsorbed oral agent being developed for the treatment of… 
Highly Cited
2008
Highly Cited
2008
ABSTRACT During a 10-day treatment for Clostridium difficile infection, OPT-80 and vancomycin were comparably effective in… 
Highly Cited
2008
Highly Cited
2008
ABSTRACT OPT-80, a novel, minimally absorbed macrocycle, is a candidate treatment option for Clostridium difficile infection (CDI… 
Highly Cited
2008
Highly Cited
2008
ABSTRACT Current therapies for Clostridium difficile infection (CDI) are encumbered by treatment failures and recurrences. Due to… 
Review
2008
Review
2008
BACKGROUND Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and… 
Highly Cited
2007
Highly Cited
2007
ABSTRACT The incidence and severity of Clostridium difficile-associated disease (CDAD) is increasing, and standard treatment is… 
Review
2007
Review
2007
  • Alan P. Johnson
  • Current opinion in investigational drugs
  • 2007
  • Corpus ID: 42242706
Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum… 
Highly Cited
2004
Highly Cited
2004
ABSTRACT Clostridium difficile remains the major cause of nosocomial diarrhea. Reports on impaired susceptibility of C. difficile… 
Highly Cited
2004
Highly Cited
2004
ABSTRACT The activities of OPT-80 against 453 intestinal bacteria were compared with those of seven other drugs. OPT-80 showed… 
Highly Cited
2004
Highly Cited
2004
ABSTRACT Agar dilution MIC was used to compare activities of OPT-80, linezolid, vancomycin, teicoplanin, quinupristin…